Altre lingue Chimeric Therapeutics Limited

Azioni

CHM

AU0000121576

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:53 31/05/2024			Variaz. 5gg	Var. 1 gen.
0,018 ^AUD	-.--%		-21,74%	-48,57%

22/05	Lo studio CHM CDH17 di Chimeric Therapeutics, primo nell'uomo, è aperto all'arruolamento; le azioni salgono del 4%.	MT
02/05	Chimeric Therapeutics nomina un COO; le azioni salgono del 4%.	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4%	22/05
Chimeric Therapeutics Appoints COO; Shares Rise 4%	02/05
Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%	01/05
Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%	05/04
Chimeric Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Chimeric Therapeutics Treats First Patient in Phase 1B Leukemia Trial	08/02
Chimeric Therapeutics Receives AU$7 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	10/01
Chimeric Therapeutics Secures AU$1 Million via Share Placement Deal	04/01
Chimeric Therapeutics Extends Closing Date of AU$10 Million Entitlement Offer	15/11
Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101	31/10/23
Australian Shares Rebound Ahead of US Fed Policy Meeting	31/10/23
US FDA Gives Green Signal to Chimeric Therapeutics' IND Application for Gastrointestinal Cancer Drug; Shares Jump 65%	31/10/23
Chimeric Therapeutics to Raise AU$10 Million from Entitlement Offer	25/10/23
Chimeric Therapeutics Signs Deal to Support Leukemia Trial	13/09/23
Chimeric Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Chimeric Therapeutics Limited Announces Board Changes	30/08/23
Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director	03/08/23
Chimeric Therapeutics Limited Announces Board Changes	12/07/23
Chimeric Therapeutics Secures Up to AU$12.6 Million for Clinical Trial, Therapy	23/06/23
Chimeric Therapeutics Completes Share Purchase Plan; Shares Rise 6%	23/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Chimeric Therapeutics Limited

Azioni

CHM

AU0000121576

Altre lingue

Filtri